Intellia Therapeutics NTLA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Intellia Therapeutics (NTLA) Business Model and Operations Summary
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Key Insights
Intellia Therapeutics (NTLA) Core Market Data and Business Metrics
Latest Closing Price
$7.3Market Cap
$703.92 MillionPrice-Earnings Ratio
-1.34Total Outstanding Shares
103.52 Million SharesTotal Employees
598Dividend
No dividendIPO Date
May 6, 2016SIC Description
In Vitro & In Vivo Diagnostic SubstancesPrimary Exchange
NASDAQHeadquarters
40 Erie Street, Cambridge, MA, 02139
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Short Interest
This information is bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Average Daily Volume: The average number of shares traded per day over the specified period.
Days to Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Short Interest | Bi-Weekly Change (%) | Settlement Date | Days to Cover |
|---|---|---|---|
| 26,688,670 Shares | +2.51% | 3/14/2025 | 8.59 |
| 26,035,739 Shares | +6.62% | 2/28/2025 | 6.07 |
| 24,418,372 Shares | +1.50% | 2/14/2025 | 9.38 |
| 24,057,390 Shares | -0.01% | 1/31/2025 | 8.18 |
| 24,060,839 Shares | +11.04% | 1/15/2025 | 7.26 |
| 21,668,143 Shares | +9.40% | 12/31/2024 | 8.78 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-356.74 Million |
| Net Cash Flow From Investing Activities | $19.94 Million |
| Net Cash Flow From Investing Activities, Continuing | $19.94 Million |
| Net Cash Flow | $-46.88 Million |
| Net Cash Flow From Financing Activities | $289.91 Million |
| Net Cash Flow From Financing Activities, Continuing | $289.91 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $43.09 Million |
| Net Income/Loss | $-522.28 Million |
| Basic Average Shares | $98.41 Million |
| Diluted Average Shares | $98.41 Million |
| Income/Loss From Continuing Operations After Tax | $-522.28 Million |
| Operating Expenses | $580.79 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-130.97 Million |
| Comprehensive Income/Loss Attributable To Parent | $-517.55 Million |
| Comprehensive Income/Loss | $-517.55 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $710.90 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Liabilities | $71.99 Million |
| Current Liabilities | $105.68 Million |
| Liabilities | $210.74 Million |
| Equity Attributable To Parent | $962.62 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||